CNMD
NYSECONMED Corporation
Price$43.21-1.59 (-3.54%)
01:30 PM07:45 PM
News · 26 weeks53-36%
2026-01-182026-07-12
Mix2890d
- Insider14(50%)
- SEC Filings7(25%)
- Earnings2(7%)
- Leadership2(7%)
- Analyst2(7%)
- Other1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Executive Vice President & CFO Gallagher John E4 - CONMED Corp (0000816956) (Issuer)
- INSIDERNew insider Gallagher John E claimed no ownership of stock in the company (SEC Form 3)3 - CONMED Corp (0000816956) (Issuer)
- ANALYSTBMO Capital Markets initiated coverage on CONMED with a new price targetBMO Capital Markets initiated coverage of CONMED with a rating of Market Perform and set a new price target of $36.00
- INSIDERSEC Form 4 filed by Director Martin Celine Christine4 - CONMED Corp (0000816956) (Issuer)
- INSIDERSEC Form 4 filed by Director Mirviss Jeffrey B.4 - CONMED Corp (0000816956) (Issuer)
- INSIDERNew insider Mirviss Jeffrey B. claimed no ownership of stock in the company (SEC Form 3)3 - CONMED Corp (0000816956) (Issuer)
- INSIDERNew insider Martin Celine Christine claimed no ownership of stock in the company (SEC Form 3)3 - CONMED Corp (0000816956) (Issuer)
- PRCONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website: https://www.conmed.com/en/investor-relations. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Cor
- ANALYSTCONMED downgraded by BofA Securities with a new price targetBofA Securities downgraded CONMED from Neutral to Underperform and set a new price target of $40.00
- SECCONMED Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure8-K - CONMED Corp (0000816956) (Filer)
- PRCONMED Corporation Appoints John E. Gallagher as Chief Financial OfficerCONMED Corporation (NYSE:CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer ("CFO"), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026. "We are pleased to welcome a talented and experienced financial executive of John's caliber to CONMED," said Patrick J. Beyer, CONMED's President and Chief Executive Officer. "John brings deep healthcare and medical technology experience, an extensive history of public company leadership, and a proven track record of leading global finance organizations and supporting complex strategic initiatives. His combination of industry experti
- SECSEC Form 11-K filed by CONMED Corporation11-K - CONMED Corp (0000816956) (Filer)
- SECCONMED Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - CONMED Corp (0000816956) (Filer)
- INSIDERDirector Bronson David M. converted options into 668 shares, increasing direct ownership by 4% to 17,909 units (SEC Form 4)4 - CONMED Corp (0000816956) (Issuer)
- INSIDERDirector Council Laverne H converted options into 668 shares, increasing direct ownership by 17% to 4,716 units (SEC Form 4)4 - CONMED Corp (0000816956) (Issuer)
- INSIDERSEC Form 4 filed by Director Kelderman Kim4 - CONMED Corp (0000816956) (Issuer)
- INSIDERDirector Farkas Charles converted options into 668 shares, increasing direct ownership by 4% to 15,527 units (SEC Form 4)4 - CONMED Corp (0000816956) (Issuer)
- INSIDERDirector Kaye Mark converted options into 668 shares, increasing direct ownership by 439% to 820 units (SEC Form 4)4 - CONMED Corp (0000816956) (Issuer)
- INSIDERDirector Schwarzentraub Barbara J converted options into 668 shares, increasing direct ownership by 15% to 5,012 units (SEC Form 4)4 - CONMED Corp (0000816956) (Issuer)
- INSIDERAmendment: New insider Lockwood Kimberly claimed ownership of 1,868 shares (SEC Form 3)3/A - CONMED Corp (0000816956) (Issuer)
- INSIDERNew insider Lockwood Kimberly claimed ownership of 1,868 shares (SEC Form 3)3 - CONMED Corp (0000816956) (Issuer)
- SECCONMED Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - CONMED Corp (0000816956) (Filer)
- SECSEC Form SD filed by CONMED CorporationSD - CONMED Corp (0000816956) (Filer)
- SECCONMED Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - CONMED Corp (0000816956) (Filer)
- PRCONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of DirectorsCONMED Corporation (NYSE:CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors ("Board"), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total of nine directors. "My fellow directors and I are delighted to welcome Celine Martin and Jeff Mirviss to the Board, both highly accomplished leaders with extensive experience developed at two of the largest companies in the healt
CNMD FAQ
7 questionsWhat does CONMED Corporation do?
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports...Where does CNMD stock trade?
CONMED Corporation (CNMD) is listed on NYSE.What sector and industry is CNMD in?
CONMED Corporation operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did CONMED Corporation go public?
CONMED Corporation (CNMD) completed its IPO in 1987.What are analysts saying about CNMD?
CONMED Corporation has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Market Perform with a $3600.00 price target on 2026-07-09. Recent price targets range from $3600.00 to $4000.00.What companies are similar to CNMD?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare CNMD side-by-side with any of them on Quantisnow.How can I track CNMD on Quantisnow?
Quantisnow aggregates CONMED Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CNMD to receive live email and push alerts on every new disclosure.